Hematologic Malignancies Demystified – New York
Meeting Series
Meeting Series

Hematologic Malignancies Demystified – New York

A Critical Appraisal of Data from 2018

Not a member of My prIME? Join now for instant access.

Explore the options in hematology and hematologic malignancies with this live meeting. Stay informed on new data with established agents and gain insight into the use of novel agents in your practice. Expert faculty will focus on updates from recent congresses and the latest clinically relevant data.

Intercontinental Times Square
300 West 44th Street
New York, NY 10036
212.803.4500

Date/Time

Date/Time

Saturday, January 19, 2019
8.00 AM - 4.00 PM

Location

Location

New York, New York, United States

CME

CME

6.5 AMA PRA Category 1 Credits™

7.00 AM Registration and continental breakfast
8.00 AM Welcome and introduction
Hagop M. Kantarjian, MD
8.10 AM Acute leukemia
Richard M. Stone, MD
8.40 AM Myelodysplastic syndromes
Guillermo Garcia-Manero, MD
9.10 AM Myeloproliferative neoplasms
Srdan Verstovsek, MD, PhD
9.40 AM Oncology Guru™ hematology quiz
9.50 AM Break
10.20 AM Chronic myelogenous leukemia
Jorge Cortes, MD
10.50 AM Hodgkin lymphoma
TBC
11.20 AM Non-Hodgkin lymphoma
TBC
11.50 AM Chronic lymphocytic leukemia
Susan O’Brien, MD
12.20 PM Oncology Guru™ hematology quiz
12.30 PM Lunch
1.30 PM Multiple myeloma
Kenneth Anderson, MD
2.10 PM Complications of transplant
Sergio Giralt, MD, FACP
2.40 PM Benign hematology
Stephan Moll, MD
3.10 PM Oncology Guru™ hematology quiz
3.20 PM Discussion and concluding remarks
3.25 PM MOC session
4.00 PM Adjourn

    Chair

  • Hagop M. Kantarjian, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Local Chair

  • Karen Seiter, MDNew York Medical College
    Valhalla, New York, United States
  • Faculty

  • Ranjana H. Advani, MDStanford Cancer Institute
    Stanford, California, United States
  • Kenneth Anderson, MDHarvard Medical School and Dana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Guillermo Garcia-Manero, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Sergio Giralt, MD, FACPMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Sagar Lonial, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • Stephan Moll, MDUniversity of North Carolina, School of Medicine
    Chapel Hill, North Carolina, United States
  • Susan O'Brien, MDUC Irvine Health
    Chao Family Comprehensive Cancer Center
    Orange, California, United States
  • Barbara Pro, MDRobert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois, United States
  • Richard M. Stone, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Srdan Verstovsek, MD, PhDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Julie Vose, MD, MBAUniversity of Nebraska Medical Center
    Omaha, Nebraska, United States

This educational activity is specifically designed for practicing medical oncologists, hematologists, registered nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in and/or involved in the treatment of patients with cancer in the United States.

After successful completion of this educational activity, participants should be able to:

Physicians

  • Analyze emerging data from clinical trials investigating established and novel treatment options
  • Distinguish the adverse event profiles of different options for hematologic malignancies and strategies to manage these side effects
  • Evaluate expert recommendations for patient selection and sequencing, biomarker use, and monitoring treatment response

Nurses

  • Analyze emerging data from clinical trials investigating established and novel treatment options
  • Identify the most common side effects associated with treatment of hematologic malignancies and appropriate strategies for prevention, recognition, and management of these events
  • Evaluate the clinical evidence supporting the utilization of cytogenetic markers, minimal residual disease and other prognostic/predictive tests, and counsel patients on their role

Chicago, Illinois

January 12, 2019
8.00 AM – 4.00 PM

Atlanta, Georgia

Saturday, January 26, 2019
8.00 AM – 4.00 PM

Houston, Texas

Saturday, February 2, 2019
8.00 AM – 4.00 PM

Fee for Activity

  • Physician, pharmacist, other healthcare professional:  $150
  • Nurse/Nurse Practitioner/Physician Assistant:  $40
  • Nonclinical attendee and pharmaceutical industry representative:  $800

Physicians receive a 50% discount if registering prior to January 1, 2019.

Fellows/Residents/Students

Use ID code FRS for complimentary registration. Credit card information will still be required for registration. A $25 “no-show” fee will be charged if you register, but fail to attend the meeting, and have not cancelled your registration. Cancellations will be accepted without incurring a fee, up to 72 hours prior to the meeting.

ONS Members

ONS members are eligible for discounted rates. Please contact us with the name of your ONS chapter for more information.

The registration fee includes all activity materials, breakfast, lunch, and refreshment breaks. prIME Oncology does not accept liability for travel, accommodations, or any other costs incurred by registrants.

Cancellation Policy

The registration fee is nonrefundable. Substitutions will be accepted up to one week prior to the meeting date with written notice.

Exhibitor Package

The exhibit fee will allow one 6’ exhibit table and complimentary registration, including meals, for two company representatives. Additional company representatives may register separately in the Industry category. Exhibit set up will be on Saturday morning at 6.00 AM and tables should remain in place for the duration of the meeting. Attendees will have the opportunity to visit the exhibits during breakfast each morning, at the morning break, and lunch before and after.

The name and email addresses of both representatives attending are required.  Please contact us for details and pricing.

Payment can be made by check or online by credit card.

PLEASE NOTE: If you choose to pay online via credit card, you will incur a 4% processing fee.

For payment by check, please make checks payable to prIME Oncology, LLC
Tax ID # 20-5392799 for the designated amount and send by overnight mail to:

prIME Oncology
5901 Peachtree Dunwoody Rd
Building C, Suite 250
Atlanta, GA 30328
Attention: Hematology 2019

Download Forms

Please download the necessary forms, complete them, and return to Lisa Willey by email.

Exhibit Registration Form
Hotel Room Request
prIME LLC W-9

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc. and Gilead Sciences, Inc.

 

Options are available to organizations interested in supporting this conference.  For more information, please contact us.

Continuing Education

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live CME activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

prIME Oncology is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity has been approved for 6.5 contact hours.
The criteria for successful completion include attending the full program and completing the evaluation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Provider

This activity is provided by The University of Texas MD Anderson Cancer Center and prIME Oncology.

  prIME Oncology Logo